# Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study

> **NCT02184689** · PHASE2,PHASE3 · COMPLETED · sponsor: **Drugs for Neglected Diseases** · enrollment: 125 (actual)

## Conditions studied

- Human African Trypanosomiasis (HAT)

## Interventions

- **DRUG:** fexinidazole

## Key facts

- **NCT ID:** NCT02184689
- **Lead sponsor:** Drugs for Neglected Diseases
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-03
- **Primary completion:** 2016-12-14
- **Final completion:** 2017-06-27
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2020-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02184689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02184689, "Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02184689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*